Current low global SARS-CoV-2 transmission supports the 94.4% market-implied probability of no new coronavirus pandemic in 2026. CDC and WHO surveillance through mid-May 2026 reports test positivity near 1%, emergency department visits at 0.1%, and declining or stable trends across most U.S. states, with dominant subvariants such as XFG and NB.1.8.1 showing no increase in severity or immune escape sufficient for pandemic potential. These data align with historical patterns of endemic Omicron-lineage circulation rather than novel strain emergence. Traders interpret ongoing genomic monitoring and absence of variants of concern as strong evidence against sustained human-to-human spread of a high-impact pathogen. A realistic challenge could arise from an undetected animal reservoir spillover producing a variant with enhanced transmissibility and virulence, though current model consensus and case thresholds make this outcome unlikely before year-end.